{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:12:53Z","timestamp":1790903573739,"version":"4.1.0"},"reference-count":69,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health, Italian Government","award":["Funds R.C. 2021"],"award-info":[{"award-number":["Funds R.C. 2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peripheral T-cell lymphoma, not otherwise specified (PTCL_NOS) corresponds to about one fourth of mature T-cell tumors, which overall represent 10\u201312% of all lymphoid malignancies. This category comprises all T-cell neoplasms, which do not correspond to any of the distinct entities listed in the WHO (World Health Organization) Classification of Tumours of Haematopoietic and Lymphoid Tissues. In spite of the extreme variability of morphologic features and phenotypic profiles, gene expression profiling (GEP) studies have shown a signature that is distinct from that of all remaining PTCLs. GEP has also allowed the identification of subtypes provided with prognostic relevance. Conversely to GEP, next-generation sequencing (NGS) has so far been applied to a limited number of cases, providing some hints to better understand the pathobiology of PTCL_NOS. Although several pieces of information have emerged from pathological studies, PTCL_NOS still remains a tumor with a dismal prognosis. The usage of CHOEP (cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide) followed by autologous stem cell transplantation may represent the best option, by curing about 50% of the patients whom such an approach can be applied to. Many new drugs have been proposed without achieving the expected results. Thus, the optimal treatment of PTCL_NOS remains unidentified.<\/jats:p>","DOI":"10.3390\/cancers13184535","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:20:37Z","timestamp":1631190037000},"page":"4535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano A.","family":"Pileri","sequence":"first","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiori","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Calleri","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-2673","authenticated-orcid":false,"given":"Federica","family":"Melle","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Motta","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lorenzini","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"},{"name":"Department of Health Sciences, University of Milan, Via di Rudin\u00ec 8, 20146 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology, Haematology Programme, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20121 Milan, Italy"},{"name":"Department of Health Sciences, University of Milan, Via di Rudin\u00ec 8, 20146 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2009.019133","article-title":"A novel subset of T-helper cells: Follicular T-helper cells and their markers","volume":"95","author":"Laurent","year":"2010","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2015-08-665075","article-title":"Follicular helper T-cell-related lymphomas","volume":"126","author":"Pileri","year":"2015","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11899-015-0291-0","article-title":"The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: The Case of COMPLETE and the T-Cell Project","volume":"10","author":"Bellei","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jncimonographs\/lgu012","article-title":"Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: The InterLymph non-Hodgkin lymphoma subtypes project","volume":"48","author":"Wang","year":"2014","journal-title":"J. Natl. Cancer. Inst. Monogr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/ejd.2016.2915","article-title":"Erythroderma and non-Hodgkin T-cell lymphoma: What else, apart from Mycosis Fungoides and S\u00e9zary syndrome?","volume":"27","author":"Pileri","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2559.2011.04069.x","article-title":"Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: What is Lennert\u2019s lymphoma nowadays?","volume":"59","author":"Hartmann","year":"2011","journal-title":"Histopathology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA level","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1097\/PAS.0000000000000295","article-title":"Cytotoxic T-cell and NK-cell lymphomas: Current questions and controversies","volume":"38","author":"Swerdlow","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/acel.12435","article-title":"Characterization of age-associated exhausted CD8+ T cells defined by increased expression of Tim-3 and PD-1","volume":"15","author":"Lee","year":"2016","journal-title":"Aging Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma\u2013NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1200\/JCO.2011.36.9280","article-title":"Peripheral T-cell lymphoma with aberrant expression of CD30, CD15, and CD20","volume":"29","author":"Song","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1309\/QBLAMA321K9AD2XK","article-title":"Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics","volume":"127","author":"Warnke","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dobson, R., Du, P.Y., R\u00e1s\u00f3-Barnett, L., Yao, W.Q., Chen, Z., Casa, C., Ei-Daly, H., Farkas, L., Soilleux, E., and Wright, P. (2021). Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica, E-pub ahead of print.","DOI":"10.3324\/haematol.2020.265991"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Cuadros","year":"2005","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/leu.2014.50","article-title":"Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway","volume":"28","author":"Piccaluga","year":"2014","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: Results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","article-title":"Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS","volume":"2","author":"Sugio","year":"2018","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Maura, F., Dodero, A., Carniti, C., Bolli, N., Magni, M., Monti, V., Cabras, A., Leongamornlert, D., Abascal, F., and Diamond, B. (2020). CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Haematologica, E-pub ahead of print.","DOI":"10.3324\/haematol.2020.262659"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1073\/pnas.1608839114","article-title":"Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas","volume":"114","author":"Abate","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41379-019-0279-8","article-title":"Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified","volume":"33","author":"Laginestra","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.3324\/haematol.2019.218305","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective International T-Cell Project","volume":"104","author":"Bellei","year":"2019","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_46","first-page":"v108","article-title":"ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"COMPLETE Investigators. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_50","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: A retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-134440","article-title":"Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.1346","article-title":"BCL-2 family proteins in peripheral T-cell lymphomas: Correlation with tumour apoptosis and proliferation","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?","volume":"92","author":"Zaja","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","article-title":"Dasatinib","volume":"201","author":"Lindauer","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"ACT-2 study investigators. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: The DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: An open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:59:48Z","timestamp":1760165988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":69,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184535"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184535","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}